Literature DB >> 26410647

Targeted Chemotherapy in Bone and Soft-Tissue Sarcoma.

Jared L Harwood1, John H Alexander1, Joel L Mayerson2, Thomas J Scharschmidt1.   

Abstract

Historically surgical intervention has been the mainstay of therapy for bone and soft-tissue sarcomas, augmented with adjuvant radiation for local control. Although cytotoxic chemotherapy revolutionized the treatment of many sarcomas, classic treatment regimens are fraught with side effects while outcomes have plateaued. However, since the approval of imatinib in 2002, research into targeted chemotherapy has increased exponentially. With targeted therapies comes the potential for decreased side effects and more potent, personalized treatment options. This article reviews the evolution of medical knowledge regarding sarcoma, the basic science of sarcomatogenesis, and the major targets and pathways now being studied.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bone; Chemotherapy; Sarcoma; Targeted; Tumor

Mesh：

Substances：

Year:  2015        PMID： 26410647     DOI： 10.1016/j.ocl.2015.06.011

Source DB:  PubMed          Journal:  Orthop Clin North Am        ISSN： 0030-5898            Impact factor:   2.472


  15 in total

1.  CORR Insights®: Is It Possible and Safe to Perform Acetabular-preserving Resections for Malignant Neoplasms of the Periacetabular Region?

Authors:  Joel L Mayerson
Journal:  Clin Orthop Relat Res       Date:  2016-04-13       Impact factor: 4.176

2.  Pulmonary metastasectomy with therapeutic intent for soft-tissue sarcoma.

Authors:  Neel P Chudgar; Murray F Brennan; Rodrigo R Munhoz; Peter R Bucciarelli; Kay See Tan; Sandra P D'Angelo; Manjit S Bains; Matthew Bott; James Huang; Bernard J Park; Valerie W Rusch; Prasad S Adusumilli; William D Tap; Samuel Singer; David R Jones
Journal:  J Thorac Cardiovasc Surg       Date:  2017-03-21       Impact factor: 5.209

3.  CORR Insights®: Is Metformin Use Associated with Prolonged Overall Survival In Patients with Soft Tissue Sarcoma? A SEER-Medicare Study.

Authors:  Joel L Mayerson
Journal:  Clin Orthop Relat Res       Date:  2022-04-01       Impact factor: 4.755

Review 4.  The roles and implications of exosomes in sarcoma.

Authors:  Li Min; Jacson Shen; Chongqi Tu; Francis Hornicek; Zhenfeng Duan
Journal:  Cancer Metastasis Rev       Date:  2016-09       Impact factor: 9.264

Review 5.  Development and potential applications of CRISPR-Cas9 genome editing technology in sarcoma.

Authors:  Tang Liu; Jacson K Shen; Zhihong Li; Edwin Choy; Francis J Hornicek; Zhenfeng Duan
Journal:  Cancer Lett       Date:  2016-01-21       Impact factor: 8.679

Review 6.  Osteosarcoma: Cells-of-Origin, Cancer Stem Cells, and Targeted Therapies.

Authors:  Ander Abarrategi; Juan Tornin; Lucia Martinez-Cruzado; Ashley Hamilton; Enrique Martinez-Campos; Juan P Rodrigo; M Victoria González; Nicola Baldini; Javier Garcia-Castro; Rene Rodriguez
Journal:  Stem Cells Int       Date:  2016-06-05       Impact factor: 5.443

Review 7.  Noncoding RNA in drug resistant sarcoma.

Authors:  Xiaoyang Li; Jacson K Shen; Francis J Hornicek; Tao Xiao; Zhenfeng Duan
Journal:  Oncotarget       Date:  2017-07-06

8.  Biological reconstruction in the treatment of extremity sarcoma in femur, tibia, and humerus.

Authors:  Weitao Yao; Qiqing Cai; Jiaqiang Wang; Peng Zhang; Xin Wang; Xinhui Du; Xiaohui Niu
Journal:  Medicine (Baltimore)       Date:  2020-07-02       Impact factor: 1.817

Review 9.  Novel molecular insights and new therapeutic strategies in osteosarcoma.

Authors:  Babak Otoukesh; Bahram Boddouhi; Mehdi Moghtadaei; Peyman Kaghazian; Maria Kaghazian
Journal:  Cancer Cell Int       Date:  2018-10-16       Impact factor: 5.722

Review 10.  Smart Cargo Delivery System based on Mesoporous Nanoparticles for Bone Disease Diagnosis and Treatment.

Authors:  Panpan Pan; Qin Yue; Juan Li; Meiqi Gao; Xuanyu Yang; Yuan Ren; Xiaowei Cheng; Penglei Cui; Yonghui Deng
Journal:  Adv Sci (Weinh)       Date:  2021-03-16       Impact factor: 16.806
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.